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Abstract
Background: Traditionally, in patients with mitral regurgitation (MR) a successful mitral valve
repair is considered when residual MR by post-pump transesophageal echocardiography (TEE) is
less than moderate or absent. Little is known about the prognostic value of less than moderate
(mild or mild-to-moderate) residual MR for the early outcome of patients treated with mitral valve
repair.
Methods: Eligible for this study were patients undergoing isolated mitral valve repair. Patients with
moderate or severe residual MR after valve repair were excluded. The primary endpoint of the
study was the composite of death or need of reintervention.
Results: A total of 98 patients (54 with no residual MR-Group 1, and 44 with less than moderate
residual MR-Group 2) were analyzed. Of these, 72% presented with New York Heart Association
(NYHA) 3/4, and 38% were women. The primary endpoint of the study occurred in 3 (5.5%)
patients in Group 1 and 6 (13.6%) patients in Group 2 MR (P = 0.31). There was a trend toward a
higher incidence of use of inotropic drugs post-interventional (P = 0.12), and a longer hospital stay
among patients with less than moderate residual MR (P = 0.18).
Conclusion: In our study population, patients with less than moderate residual MR had a trend
toward a higher risk of early adverse outcomes as compared with patients with no residual MR by
post-pump TEE. Studies with a larger patient population and longer follow-up data may be useful
to better define the clinical significance of residual mild MR after mitral vale repair.
Background
Mitral regurgitation is the most commonly encountered
valve lesion in modern clinical practice [1]. As echocardi-
ography is the most widely available cardiac imaging
modality, it is the technique which is routinely used to
assess patients with suspected or known MR. Echo-Dop-
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pler is an excellent technique for detecting the presence of
MR and defining the underlying pathological cause [2].
Echo-Doppler grading of regurgitation severity in con-
junction with patient symptoms and signs and occasion-
ally invasive haemodynamic information are useful in the
decision-making process with respect to the need for and
timing of mitral valve surgery [2].
It is important to note that mitral regurgitation changed in
the last decades with regard to its etiologic profile, which
is now dominated by degenerative and ischemic causes in
developed countries [3]; to its noninvasive assessment
with the developments in transesophageal echocardiogra-
phy (TEE), colour flow imaging, and new methods of
quantization of regurgitation [1]; and to its management
with improved understanding of the role of left ventricle
(LV) function in prognosis [2]. Most importantly,
advances in conservative surgery have improved its treat-
ment [4].
The post-Cardiac Pulmonary Bypass (CPB) TEE exam is
essential in helping to determine the competency of the
repaired mitral valve (MV), and to evaluate persistent MR
[5]. Hemodynamic loading conditions and left ventricle
function also must be taken into consideration in the
assessment of residual MR [6]. Following MV procedures,
several studies have suggested that, in approximately 5–
11% of cases the post-CPB TEE exam may identify persist-
ent lesions that require additional immediate surgical
intervention [7,8]. Moderate to severe residual MR will
necessitate a return to CPB for further evaluation and
repeat surgery.
The aim of the present retrospective study was to assess
the short-term outcome of patients who underwent mitral
valve repair in our Cardiac Surgery Division with less than
moderate mitral regurgitation after repair.
Methods
Data source
To collect the necessary information for this study we used
the database of patients admitted and treated at Ospedale
Pasquinucci, IFC-CNR, Massa, Italy from January 2004 to
October 2005.
Patient population
Eligible for inclusion in this study were considered all
patients who consecutively underwent mitral valve
replacement for mitral regurgitation with no or less than
moderate residual post-pump mitral regurgitation at the
service of cardiac surgery for the adults at our Institution.
Patients who underwent mitral valve repair in conjunc-
tion with other planned cardiovascular surgical interven-
tions such as coronary bypass artery grafting, other cardiac
valve surgery, previous mitral valve repair, interventions
for abdominal or thoracic aortic disease or accompanying
congenital malformations were excluded from the study.
On the other hand, no restriction criteria were imposed
with respect to age, symptoms at baseline or presence of
concomitant diseases. Although this was a retrospective
study, all data have been prospectively collected and
entered into the above-mentioned hospital database.
Overall, 98 patients with no or mild residual mitral regur-
gitation were included in this study. These were divided
into two groups: those with no residual mitral regurgita-
tion and those with less than moderate (mild and mild-
to-moderate) residual mitral regurgitation. The first group
consisted of 54 patients and the second group consisted of
44 patients.
Etiology of mitral regurgitation
Possible causes included primary valve and functional
causes: mitral valve prolapse, rheumatic heart disease,
endocarditis, papillary muscle rupture, congenital, mitral
annular dilatation, left ventricular wall motion abnormal-
ity. Patients with previous mitral valve repair were
excluded from the study.
Methodology used for the measurement of mitral 
regurgitation
The severity of mitral regurgitation was graded according
the recommendation of the American Society of Echocar-
diography [9]. Preoperative transthoracic assessment was
performed using a General Electrics Vivid 7 dimension
echographer with a 3 MHz cardiologic probe (General
Electrics mod. 2323337 3S). Postoperative assessment
was performed at the end of cardiopulmonary by-pass
with a Philips Sonos 7500 echographer and a 5 MHz tran-
soesophageal multiplane transducer (Hewlett Packard
mod.21378A). Postoperative mitral regurgitation was
evaluated as stated in guidelines [9] with a semiquantita-
tive grading from absent to severe.
Endpoints and definitions
The primary endpoint of the study was the composite of
death and need of reintervention for recurrent severe
mitral regurgitation. Other outcomes of interest were the
need for intraoartic balloon pump and inotropic drugs in
the immediate period after the intervention, intubation
time (time to extubation after the intervention) and
length of stay in the intensive care unit as well as total
length of hospital stay. Other complications such as
bleeding, ischemic complications, respiratory complica-
tions, renal failure and wound infection were also evalu-
ated. The type of required reintervention was also
documented. Arterial hypertension was defined as systolic
blood pressure of ≥140 mmHg and/or diastolic blood
pressure of ≥90 mmHg on at least 2 separate occasions or
the treatment with antihypertensive agents. Hypercholes-Cardiovascular Ultrasound 2007, 5:25 http://www.cardiovascularultrasound.com/content/5/1/25
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terolemia was defined as total cholesterol ≥240 mg/dl or
treatment with a lipid-lowering agent.
Statistical analysis
All data presented are shown as mean ± standard devia-
tion or numbers (percentages). To compare the differ-
ences between groups, we used student t  test for
continuous data and chi-square or Fisher's exact test for
categorical data, as appropriate. Statistical significance
was accepted for a two-tailed P < 0.05.
Results
Baseline clinical characteristics
A total of 98 patients, 54 patients with no residual mitral
regurgitation and 44 patients with less than moderate
residual mitral regurgitation of were available for the anal-
ysis. Most of the patients presented with NYHA 3/4
(62%). Women constituted 38% of the study population
while 27% of the patients had diabetes mellitus. Around
41% of the patients included in this study had hyperlipi-
demia, 49% had arterial hypertension while 17% of them
were current smokers. Mean body mass index, was 29 ±
3.2 kg/m2 for this patient population. From the overall
study population, 12% of the patients had angiographi-
cally documented coronary artery disease and 11% of
them had a history of prior myocardial infarction. From
the total study population, 13% of the patients had previ-
ously undergone a cardiovascular intervention (coronary
bypass artery grafting, percutaneous coronary interven-
tions or surgical treatment for aortic disease). Atrial fibril-
lation was diagnosed in 25% of the patients at baseline.
There were no statistically significant differences with
respect the baseline clinical and characteristics between
the patients who had no residual mitral regurgitation or
less than moderate residual mitral regurgitation at the
post-pump TEE (Table 1).
Baseline echocardiographic characteristics (transthoracic 
echocardiogram)
Of the total patient population, 50% had moderate MR
and 50% severe MR. Mean pulmonary artery systolic pres-
sure was 41 ± 8.9 mmHg and mean left atrium size 45 ±
6.3 mm. Mean ejection fraction of left ventricle was 57%
in the total study population. Similar to the baseline clin-
ical characteristics, there was no statistically significant
difference between the 2 study groups with respect to
baseline transthoracic echocardiographic indexes (Table
2).
Causes of mitral regurgitation (transesophageal 
echocardiography)
In most of the cases the cause of MR was mitral valve pro-
lapse (73%). The second most frequent cause was left ven-
tricular wall motion abnormalities, which were present in
25% of the patients. Mitral annular dilatation (11%), pap-
illary muscle rupture (5%), rheumatic heart disease (4%),
endocarditis (4%) and congenital anomaly of mitral valve
(1%) were less frequently reported. In some patients more
than one of the above-mentioned causes of MR was
present. These causes were non-differently distributed
between patients with no residual MR and patients less
than moderate residual MR (Table 3).
In hospital outcomes, complications and re-interventions
The primary endpoint of the study, the composite of in-
hospital death or need of reintervention for recurrent
severe mitral regurgitation in 3 (5.5%) patients with no
residual MR and 6 (13.6%) patients with less than moder-
ate residual MR (Figure 1, P = 0.31). In the group with no
residual MR 1 (2%) patient died and another patient suf-
fered a stroke. There were no deaths or strokes among
patients with less than moderate residual MR, but 1 (2%)
patient in this group had a thrombotic episode of an infe-
rior limb which was treated percutaneously. Two (3.7%)
Table 1: Baseline characteristics.
Variables Group 1 (n = 54) Group 2 (n = 44) P value
Age, years 62.3 ± 11.5 66.6 ± 10.5 0.11
Women, n (%) 19 (35) 18 (41) 0.56
Weight, kg 73.4 ± 14.7 68.9 ± 13.7 0.13
Height, cm 172.1 ± 9.0 168.9 ± 8.9 0.07
Body mass index, kg/m2 24.9 ± 3.9 24.0 ± 3.4 0.40
Current smoker, n (%) 10 (19) 7 (16) 0.73
Diabetes mellitus, n (%) 15 (28) 11 (25) 0.76
Hyperlipidemia, n (%) 22 (41) 17(39) 0.83
Arterial hypertension, n (%) 22 (41) 24 (55) 0.17
Ejection fraction, % 57.9 ± 9.4 55.3 ± 8.3 0.13
NYHA 3/4, n (%) 30 (56) 31 (70) 0.20
COPD, n (%) 9 (17) 6 (14) 0.68
Other concomitant diseases, n (%) 13 (19) 10 (16) 0.88
NYHA-New York Heart Association (classification). COPD-chronic obstructive pulmonary disease. Group 1-no residual mitral regurgitation. 
Group 2-less than moderate mitral regurgitation.Cardiovascular Ultrasound 2007, 5:25 http://www.cardiovascularultrasound.com/content/5/1/25
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patients with no residual MR and 6 (13.6%) of the
patients with less than moderate residual MR had recur-
rent severe mitral regurgitation (P = 0.16). Patients with
no residual MR underwent mitral valve replacement while
3 of the 6 patients with less than moderate residual MR
underwent repeat valve replacement and the other 3
patients underwent mitral valve repair. Bleeding compli-
cations were reported in 2 (4%) patients in the first group
and 2 (%) in the second group (P = 0.85). These patients
were either re-opened or had a drain placed. Any of the
following complications: recurrent several mitral regurgi-
tation, bleeding, cognitive damage, respiratory complica-
tions, stroke limb ischemia, wound infection or renal
failure occurred in 9 (17%) patients with no residual MR
and 15 (34%) patients with less than moderate residual
MR (P = 0.08) (Tables 4, 5 and 6).
Only 2 patients in each group required implantation of
intraaortic balloon (4% vs 5%, P = 0.85). A marginally
non-significant difference was observed with regard to the
need for inotropic drugs (P = 0.12). Patients with less than
moderate residual MR had a marginally significant longer
intubation time (P = 0.04). Mean length of stay in the ICU
and total length of stay were not significantly different
between the 2 groups (respectively P = 0.84 and P = 0.18,
Table 6).
Discussion
In this study we evaluated the prognostic value for the
early adverse outcomes of mild residual MR, as assessed
by post-pump transesophageal echocardiography, after
valve repair in patients with mitral valve regurgitation. We
found an increased risk, though statistically not signifi-
cant, among patients with less than moderate MR as com-
pared to those with no residual mitral regurgitation with
respect to the composite of early adverse outcomes as well
as postintervention complications. Our findings suggest
that in a patient population with characteristics similar to
the one evaluated in our study, less than moderate resid-
ual regurgitation might negatively influence the outcome
of patients who have undergone mitral vale repair. This
hypothesis should be further explored.
The post-CPB TEE examination plays a major role in the
establishing the competency of the repaired MV, and to
evaluate persistent MR. Hemodynamic loading condi-
tions and LV function must also be taken into considera-
tion in the assessment of residual MR. Following MV
procedures, several studies have suggested that, in approx-
imately 5–11% of cases the post-CPB TEE exam may iden-
Incidence of the primary endpoint (composite of in-hospital  death or need of reintervention) in Group 1 (patients with  no residual mitral regurgitation) and Group 2 (less than mod- erate residual mitral regurgitation) Figure 1
Incidence of the primary endpoint (composite of in-hospital 
death or need of reintervention) in Group 1 (patients with 
no residual mitral regurgitation) and Group 2 (less than mod-






















































Table 3: Causes of mitral regurgitation (transesophageal 
ECHO).





Mitral valve prolapse, n (%) 43 (80) 29 (66) 0.13
Rheumatic heart disease, n (%) 2 (4) 2 (5) 0.82
Endocarditis, n (%) 3 (6) 1 (2) 0.78
Chordal rupture, n (%) 4 (7) 1 (2) 0.50
Congenital anomaly, n (%) 1 (2) 0 (0) 0.91
Mitral annular dilatation, n (%) 6 (11) 5 (11) 0.97
Left ventricular wall motion 
abnormality, n (%)
13 (24) 11 (25) 0.92
Table 2: Baseline echocardiographic data (transthoracic ECHO)




Moderate, n (%) 26 (48) 23 (52)
Severe, n (%) 28 (52) 21 (48)
PASP, mmHg 40.9 ± 8.8 41.6 ± 10.6 0.70
Left atrium size, mm 44.9 ± 6.4 45.8 ± 6.1 0.49
PSAP-pulmonary artery systolic pressure.
Table 4: In hospital outcomes.





Death, n (%) 1 (2) 0 (0) 0.91
Intraaortic balloon, n (%) 2 (4) 2 (5) 0.85
Inotropic drugs, n (%) 21 (39) 55 (47) 0.12
Intubation time, hours 9.3 ± 6.9 12.6 ± 9.2 0.04
Length of stay in ICU, days 1.3 ± 1.3 1.4 ± 0.7 0.84
Total hospital stay, days 8.7 ± 3.3 9.7 ± 3.8 0.18
ICU-intensive care unit.Cardiovascular Ultrasound 2007, 5:25 http://www.cardiovascularultrasound.com/content/5/1/25
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tify persistent lesions that require additional immediate
surgical intervention [7,8]. Residual moderate or severe
MR will usually necessitate a return to CPB for further
evaluation and definitive surgery. However, little is
known about the outcome of patients who have less than
moderate residual MR after repair evaluated by means of
intraoperative TEE.
In an early study, Fix et al. analyzed early outcomes
among 76 patients with grade mild-to-moderate residual
MR by post-pump intraoperative echocardiography and
compared them with 76 well-matched patients who had
no residual MR by post-pump echocardiography [10]. In-
hospital morbidity measured by the frequency of respira-
tory complications, strokes, time in intensive care unit,
and duration of hospital stay was reported to be higher in
the patients with no residual MR after repair. Hospital
mortality was not significantly different. Similar to this
study we found no difference in in-hospital mortality
among patients with different grades of residual MR.
However, differently from this study we did not found a
significant difference in in-hospital morbidity between
patients with no residual MI and less than moderate resid-
ual MI. Moreover, we found a trend favouring patients
with no residual MI with respect to the need of reinterven-
tion for recurrent severe mitral regurgitation and a com-
posite of postintervention complications. The different
results between our study and that of Fix et al. [10] should
be sought in the different patients included (e.g. in con-
trast to Fix et al. we excluded patients who underwent con-
comitant cardiovascular surgery) as well as different time
periods in which patients of the respective studies were
operated (more than 15 years difference) which may
reflect differences in valve repair techniques, operator
skills, pre- and post-operative care and adjunctive treat-
ments.
Only 1 (1%) patient died in the early peri-interventional
period in our study. This is consistent with the reports of
literature according to which the outcome of mitral valve
repair is dependent on the underlying disease with an
operative mortality after mitral valve repair ranging from
0–5% in patients with degenerative MR [11] to 7–26% in
patients with ischemic MR [12]. In our study, in the
majority of the patients that were included the cause of
MR was degeneration of MV.
The low risk profile our study population as well the small
number of patients that were evaluated, may be responsi-
ble for the lack of differences between the 2 groups in our
study. As stated above, there was a trend toward a more
frequent need for repeat reinterventions for recurrent
severe mitral regurgitation among patients with mild
residual MI (P = 0.16) with even a more pronounced
trend when the composite of complications was assessed
(P = 0.08). On the other hand, although both groups were
well matched with respect to the baseline clinical and
echocardiographic characteristics and causes of MR, there
might have been important occult differences between the
2 study groups. A limitation of this study is also the lack
of a longer clinical follow-up.
Conclusion
In a patient population with characteristics similar to that
evaluated in our study, less than moderate residual MR by
post-pump TEE after mitral valve repair for mitral regurgi-
tation appears to confer an increased risk for adverse out-
comes during the early post-intervention period as
compared to the lack of residual MR. Studies with a larger
patient population and longer follow-up data are required
to better characterize the clinical importance of less than
moderate residual MR after mitral vale repair.
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Table 5: Complications.





Bleeding, n (%) 2 (4) 2 (5) 0.85
Recurrent severe mitral 
regurgitation, n (%)
2 (4) 6 (14) 0.16
Cognitive damage, n (%) 2 (4) 3 (7) 0.81
Respiratory complications, n 
(%)
2 (4) 4 (9) 0.49
Stroke, n (%) 1 (2) 0 (0) 0.91
Wound infection, n (%) 1 (2) 3 (7) 0.47
Limb ischemia, n (%) 0 (0) 1 (2) 0.90
Renal insufficiency, n (%) 0 (0) 1 (2) 0.90
Any of the above, n (%) 9 (17) 15 (34) 0.08
Other, % 2 (4) 2 (5) 0.85
ICU-intensive care unit. Other includes, laceration of aorta during the 
intervention and subcutaneous emphysema.
Table 6: Reinterventions.





Total reinterventions, n (%) 4 (7) 7 (16) 0.32
Reintervention for bleeding, n 
(%)
2 (4) 1 (2) 0.87
Mitral valve replacement, n (%) 2 (4) 3 (7) 0.81
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